It’s been a painful day for most biotech stocks after Janet Yellen said that smaller ones look pricey. And even Gilead Sciences (GILD) has plunged, despite the fact that Johnson & Johnson (JNJ) earnings hinted at big sales for hepatitis C drug Sovaldi.
Special to The ChronicleToday, Johnson & Johnson said it earned $1.66 a share on revenue of $4.3 billion. A big part of that beat came from booming sales of its new hepatitis-C drug Olysio. RBC Capital Market’s Michael Yee and team explain why that’s good news for Gilead:
Johnson & Johnson� Olysio US sales were $725M, up from Q1 US sales of $291M. Using our Olysio-Sovaldi sales conversion APP calculator, this implies strong US Sovaldi Q2 sales of potentially $2.8-3.2B+ (our app takes�Johnson & Johnson sales and determined a 91% capture rate for scripts; we assume $80M of�Johnson & Johnson was stocking; the higher end estimate is based on using IMS/WK sales capture rate of 70-80% and applying that to�Gilead Sciences IMS sales).
Top 5 Asian Stocks To Buy Right Now: Ion Geophysical Corporation (IO)
ION Geophysical Corporation provides planning and seismic processing services, software, and acquisition equipment to the energy industry worldwide. Its Solutions segment provides seismic data processing services for marine and land environments, reservoir solutions, onboard processing and quality control, and seismic data libraries, as well as services to manage the seismic process that comprise survey planning and design, data acquisition and management, pre-processing, and final subsurface imaging. The company�s Systems segment offers DigiSTREAMER system, a towed streamer; redeployable ocean bottom cable seismic data acquisition systems; shipboard recorders; DigiCOURSE, a marine streamer positioning system; DigiFIN streamer control systems; source and source control systems, such as air guns; and analog geophone sensors. Its Software segment provides software systems and services comprising Orca, a command and control software for towed streamer acquisition; Gator, an integrated navigation and data management software system for multi-vessel ocean bottom cable and transition zone operations; and post-survey tools, including Reflex software for seismic coverage and attribute analysis, as well as Optimiser, a technology planning tool. This segment also offers consulting services for planning, designing, and supervising surveys, including 4D and WATS survey operations. ION Geophysical Corporation also offers cable-based, cable less, and radio-controlled seismic data acquisition systems; digital sensors; vibroseis vehicles, such as vibrator trucks; and source controllers for detonator and energy sources. The company was formerly known as Input/Output, Inc. ION Geophysical Corporation was founded in 1968 and is headquartered in Houston, Texas.
Advisors' Opinion:- [By Roberto Pedone]
ION Geophysical (IO) is a technology-focused seismic solutions company that provides advanced seismic data acquisition equipment, seismic software and seismic planning, processing and interpretation services to the global energy industry. This stock closed up 1.7% to $5.35 in Tuesday's trading session.
Tuesday's Range: $5.22-$5.38
52-Week Range: $4.59-$7.70
Thursday's Volume: 1.14 million
Three-Month Average Volume: 1.12 millionFrom a technical perspective, IO rose modestly higher here right of some near-term support at $5.20 with above-average volume. This stock recently gapped up sharply from around $4.80 to $5.52 with strong upside volume. Following that move, shares of IO pulled back to $5.20 and the stock has now started to trend into its 50-day moving average of $5.36. That move is quickly pushing shares of IO within range of triggering a near-term breakout trade. That trade will hit if IO manages to take out some near-term overhead resistance levels at Tuesday's high of $5.38 to more resistance at $5.52 with high volume.
Traders should now look for long-biased trades in IO as long as it's trending above $5.20 and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.12 million shares. If that breakout triggers soon, then IO will set up to re-test or possibly take out its next major overhead resistance levels at $6 to its 200-day moving average at $6.20. Any high-volume move above $6.20 will then put $6.50 to $6.70 into range for shares of IO.
Top 10 Tech Stocks To Watch For 2014: Redhill Biopharma Ltd (RDHL)
Redhill Biopharma Ltd. is an Israel-based biopharmaceutical company. The Company is focused on the development and acquisition of therapeutic candidates. The Company�� pipeline consists of six late clinical development therapeutic candidates, two of which have completed bioequivalence clinical trials subject to review and approval by the United States Food and Drug Administration and, in some cases, regulatory authorities in other countries. The Company�� six clinical stage therapeutic candidates include RHB-101, RHB-102, RHB-103, RHB-104, RHB-105 and RHB-106.
RHB-101
RHB-101 is a treatment of hypertension, heart failure and left ventricular dysfunction (following myocardial infraction) by means of controlled release of an active ingredient known as carvedilol, which is designed to be administered to patients on a once-daily basis. RHB-101 is based on a patented technology for the controlled release of drugs administered orally.
RHB-102
RHB-102 is a once-daily controlled release oral formulation of ondansetron. RHB-102 utilizes a technology called CDT that uses salts to provide a controlled release of ondansetron.
RHB-103
RHB-103 is an oral thin film formulation of rizatriptan intended for the treatment of acute migraine headaches. Migraine is a neurovascular disorder (related to nerves and blood vessels) characterized by recurrent headaches in one side or both sides of the head.
The product is based on a technology called VersaFilm.
RHB-104
RHB-104 is an antibiotic combination therapy for the treatment of Crohn's disease (with a PIII clinical study underway), as well as Multiple Sclerosis (with an ongoing PIIa clinical study) and Rheumatoid Arthritis. RHB-104 is a combination of clarithromycin, clofazimine and rifabutin, three generic antibiotic ingredients, in a single capsule.
RHB-105
RHB-105, an antibiotics and proton pump inhibitor drug targeting Helico! bacter Pylori infection. RHB-105 is a combination of three approved drug products omeprazole, which is a proton pump inhibitor (the natural body pump that produces the gastric acids used for digesting the food in the stomach), and amoxicillin and rifabutin which are antibiotics. Chronic infection with Helicobacter pylori irritates the mucosal lining of the stomach and small intestine.
RHB-106
RHB-106, is a tablet for the preparation and cleansing of the gastrointestinal tract prior to the performance of abdominal procedures. Its abdominal procedures include diagnostic tests, such as colonoscopy, barium enema or virtual colonoscopy, as well as surgical interventions, such as laparotomy.
The company competes with GlaxoSmithKline, Sanofi-Aventis Groupe, Hoffman-La Roche Ltd, Merck and Co., Inc, Ferring Pharmaceuticals and Salix Pharmaceuticals Inc.
Advisors' Opinion:- [By Monica Gerson]
Breaking news
Vitran Corporation (NASDAQ: VTNC) announced today that it has entered into a definitive arrangement agreement with TransForce pursuant to which TransForce has agreed to acquire all of the outstanding common shares of Vitran not already owned by TransForce for US$6.50 in cash per share, in accordance with TransForce's prior proposal. To read the full news, click here. ReneSola (NYSE: SOL) today announced it signed a Memorandum of Intent (MOI) to sell three utility-scale projects in Western China, with a total capacity of 60MW, to Jiangsu Akcome Solar Science & Technology Co on December 30, 2013. To read the full news, click here. Cooper Tire & Rubber Company (NYSE: CTB) today announced it has terminated the merger agreement with Apollo Tyres (NSE:ApolloTYRE). To read the full news, click here. RedHill Biopharma (NASDAQ: RDHL) today announced that it has entered into a definitive agreement with leading healthcare investor OrbiMed Israel Partners Limited Partnership, an affiliate of OrbiMed Advisors LLC, for the sale of RedHill's American Depository Shares and warrants in a private placement transactionor a total sum of $6.0 million. To read the full news, click here.Posted-In: Guggenheim US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets
Top 10 Tech Stocks To Watch For 2014: Solera Holdings Inc.(SLH)
Solera Holdings, Inc., together with its subsidiaries, provides software and services to the automobile insurance claims processing industry. The company offers estimating and workflow software to manage the overall claims process, estimate the cost to repair a damaged vehicle, and calculate the pre-collision fair market value of a vehicle; and salvage, salvage disposition, and recycling software that manages inventories in order to facilitate the location, sale, and exchange of vehicle parts for use in the repair of a damaged vehicle. It also provides business intelligence and consulting services that enable insurance companies to monitor and assess their performance through customized data, reports, and analyses; and leases hardware products for use with its software, training, and call center technical support services. In addition, the company offers various services that allow its customers to access operational and technical support in times of high demand following natural disasters; and used vehicle validation, fraud detection software and services, and disposition of salvage vehicles. Further, it provides products and services for accessing information on the United Kingdom registered vehicles to private car buyers, car dealers, finance houses, and the insurance industry; data analytics to insurance companies and brokers in the Netherlands; and an electronic exchange for the purchase and sale of vehicle replacement parts in Brazil and Mexico. The company primarily serves insurance companies, collision repair facilities, independent assessors, and automotive recyclers in North America, Central and South America, Europe, the Middle East, Africa, Asia, Australia, and the Netherlands. Solera Holdings, Inc. was founded in 1966 and is headquartered in Westlake, Texas.
Advisors' Opinion:- [By Rich Smith]
Westlake, Texas-based Solera Holdings (NYSE: SLH ) describes its business strategy as "Leverage, Diversify, and Disrupt." That sounds like a noisy strategy, but so far, the maker of software for the automotive insurance industry is keeping quiet as a mouse about the details.
Top 10 Tech Stocks To Watch For 2014: Plexus Corp.(PLXS)
Plexus Corp., together with its subsidiaries, provides electronic manufacturing services to original equipment manufacturers and other technology companies. The company offers product development and design services, including program management, feasibility studies, product conceptualization, specification development, circuit design, field programmable gate array design, printed circuit board layout, embedded software design, mechanical design, development of test specifications, and product verification testing. It also provides value-added services, such as engineering change-order management, cost reduction redesign, component obsolescence management, product feature expansion, test enhancement, and component re-sourcing. In addition, the company offers prototyping and new product introduction services comprising assembly of prototype products, materials management, analysis of the manufacturability and testability of a design, test implementation, and pilot productio n. Further, it provides test equipment development; material sourcing and procurement; agile manufacturing; fulfillment and logistic; after-market support; and regulatory requirements services. The company serves the wireline/networking, wireless infrastructure, medical, industrial/commercial, and defense/security/aerospace markets in the United States, Malaysia, China, the United Kingdom, Mexico, and Romania. Plexus Corp. was founded in 1979 and is headquartered in Neenah, Wisconsin.
Advisors' Opinion:- [By Jake L'Ecuyer]
Equities Trading UP
Plexus (NASDAQ: PLXS) shares shot up 6.98 percent to $42.09 after the company reported its Q2 earnings of $0.60 per share on revenue of $557.60 million. The company also issued a strong Q3 outlook. - [By Evan Niu, CFA]
What: Shares of Plexus (NASDAQ: PLXS ) have jumped today by as much as 13% after the company reported earnings results.
So what: Revenue in the fiscal third quarter totaled $571.9 million, well ahead of the Street consensus of $565 million. Earnings per share were $0.68, similarly topping expectations of just $0.58 per share. CEO Dean Foate said the strong results were driven by the networking and communications as well as the health care and life sciences sectors.
- [By Seth Jayson]
Plexus (Nasdaq: PLXS ) reported earnings on July 17. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 29 (Q3), Plexus beat slightly on revenues and beat expectations on earnings per share.
Top 10 Tech Stocks To Watch For 2014: Medivation Inc.(MDVN)
Medivation, Inc., a biopharmaceutical company, focuses on the development of small molecule drugs for the treatment of castration-resistant prostate cancer, Alzheimer?s disease, and Huntington disease. The company?s product candidates under clinical development include MDV3100, which is in Phase 3 development for the treatment of castration-resistant prostate cancer; and dimebon, which is in Phase 3 clinical trial for the treatment of Alzheimer?s disease and Huntington disease. It has collaboration agreements with Pfizer Inc. to develop and commercialize dimebon; and Astellas Pharma Inc. to develop and commercialize MDV3100. The company was founded in 2003 and is based in San Francisco, California.
Advisors' Opinion:- [By Sean Williams]
A slew of competitors
We've had two treatments recently approved by the FDA a full three months ahead of their PDUFA date: Medivation (NASDAQ: MDVN ) and Astella Pharma's Xtandi, and Bayer and Algeta's Xofigo. Xtandi improved median overall survival to 18.4 months, compared with just 13.6 months for the placebo in trials while Xofigo's median overall survival tallied 14 months, compared with 11.2 months for the control arm.
Top 10 Tech Stocks To Watch For 2014: AMAG Pharmaceuticals Inc.(AMAG)
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). Its principal product includes Feraheme (ferumoxytol) injection for intravenous (IV) use, which was approved for marketing in the United States in June 2009 by the U.S. Food and Drug Administration, for use as an IV iron replacement therapy for the treatment of IDA in adult patients with chronic kidney disease (CKD). The company is pursuing marketing applications in the European Union, Canada, and Switzerland for Feraheme for the treatment of IDA in CKD patients. AMAG Pharmaceuticals was founded in 1981 and is based in Lexington, Massachusetts.
Advisors' Opinion:- [By Monica Gerson]
AMAG Pharmaceuticals (NASDAQ: AMAG) shares fell 16% to $18.38 in the pre-market trading after the company received a CRL from the FDA for the supplemental NDA for Feraheme for broader IDA indication.
Top 10 Tech Stocks To Watch For 2014: NCI Inc.(NCIT)
NCI, Inc. provides information technology (IT) and professional services and solutions to the United States Federal Government defense, intelligence, and civilian agencies. It offers enterprise systems management services, including infrastructure operations and management; outsourcing and managed; infrastructure consolidation and modernization; public/private cloud computing; planning and disaster recovery; virtual desktop infrastructure; application and network management; network design, implementation, and migration; network monitoring and performance evaluation; multi-site environments; and data center modernization and consolidation. The company also provides network engineering services comprising architecture development and design; protocol and topology optimization; disaster response planning and recovery; installation, test, and evaluation; network configuration and compliance audit; network security evaluation; protocol and topology optimization; reliability an d contingency assessment; requirements analysis; redundant routing/switching solutions; and enterprise vulnerability management. In addition, it offers cybersecurity and information assurance services consisting of intrusion detection/prevention system development; public key infrastructure implementation; certification and accreditation; computer forensics and ediscovery; policy and procedures development; threat assessment and mitigation; products evaluation and integration; security test and evaluation; cybersecurity fusion centers; and risk management and continuous monitoring. Further, the company provides software development and systems engineering services; program management and lifecycle support services; professional engineering, logistics, and support services; health IT and informatics services; and modeling, simulation, and training services. NCI, Inc. is headquartered in Reston, Virginia.
Advisors' Opinion:- [By CRWE]
NCI, Inc. (NASDAQ:NCIT) will issue its third quarter 2012 financial results after the market closes on Wednesday, October 31, 2012. Management will then discuss the results, as well as operating trends and future performance expectations, on a conference call beginning at 4:30 p.m. Eastern Time.
No comments:
Post a Comment